These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35917650)

  • 1. Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial.
    Salehi A; Namaei P; TaghaviZanjani F; Bagheri S; Moradi K; Khodaei Ardakani MR; Akhondzadeh S
    Psychiatry Res; 2022 Oct; 316():114737. PubMed ID: 35917650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial.
    Abedini T; Hosseyni R; Ghannadi F; Moghaddam HS; Ardakani MK; Talaei A; Akhondzadeh S
    Psychiatry Clin Neurosci; 2022 Oct; 76(10):505-511. PubMed ID: 35737597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
    CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
    J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A; Gholamian F; Tabatabei-Motlagh M; Afarideh M; Rezaei F; Ghazizadeh-Hashemi M; Akhondzadeh S
    Hum Psychopharmacol; 2018 Jul; 33(4):e2662. PubMed ID: 29901250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia.
    Khodaie-Ardakani MR; Khosravi M; Zarinfard R; Nejati S; Mohsenian A; Tabrizi M; Akhondzadeh S
    Acta Med Iran; 2015; 53(6):337-45. PubMed ID: 26069170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.
    Karbalaee M; Jameie M; Amanollahi M; TaghaviZanjani F; Parsaei M; Basti FA; Mokhtari S; Moradi K; Ardakani MK; Akhondzadeh S
    Schizophr Res; 2023 Apr; 254():92-98. PubMed ID: 36805834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial.
    Samaei A; Moradi K; Bagheri S; Ashraf-Ganjouei A; Alikhani R; Mousavi SB; Rezaei F; Akhondzadeh S
    Int J Neuropsychopharmacol; 2020 Dec; 23(12):775-782. PubMed ID: 33372679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-Theanine adjunct to risperidone in the treatment of chronic schizophrenia inpatients: a randomized, double-blind, placebo-controlled clinical trial.
    Shamabadi A; Fattollahzadeh-Noor S; Fallahpour B; A Basti F; Khodaei Ardakani MR; Akhondzadeh S
    Psychopharmacology (Berl); 2023 Dec; 240(12):2631-2640. PubMed ID: 37697164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.
    Anil Yağcioğlu AE; Kivircik Akdede BB; Turgut TI; Tümüklü M; Yazici MK; Alptekin K; Ertuğrul A; Jayathilake K; Göğüş A; Tunca Z; Meltzer HY
    J Clin Psychiatry; 2005 Jan; 66(1):63-72. PubMed ID: 15669890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A; Khoaie-Ardakani MR; Shahmoradi Z; Alavi AR; Afarideh M; Shalbafan MR; Ghazizadeh-Hashemi M; Akhondzadeh S
    Psychiatry Res; 2018 Apr; 262():94-101. PubMed ID: 29427913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial.
    Moazen-Zadeh E; Bayanati S; Ziafat K; Rezaei F; Mesgarpour B; Akhondzadeh S
    J Psychopharmacol; 2020 May; 34(5):506-513. PubMed ID: 32122230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
    Rezaei F; Mohammad-Karimi M; Seddighi S; Modabbernia A; Ashrafi M; Salehi B; Hammidi S; Motasami H; Hajiaghaee R; Tabrizi M; Akhondzadeh S
    J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
    Farokhnia M; Sabzabadi M; Pourmahmoud H; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Akhondzadeh S
    Psychopharmacology (Berl); 2014 Feb; 231(3):533-42. PubMed ID: 24013610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study.
    Rezaei F; Mesgarpour B; Jeddian A; Zeionoddini A; Mohammadinejad P; Salardini E; Shahriari M; Zeinoddini A; Akhondzadeh S
    Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28421639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.
    Zhong KX; Sweitzer DE; Hamer RM; Lieberman JA
    J Clin Psychiatry; 2006 Jul; 67(7):1093-103. PubMed ID: 16889453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial.
    Zeinoddini A; Ahadi M; Farokhnia M; Rezaei F; Tabrizi M; Akhondzadeh S
    J Psychiatr Res; 2014 Dec; 59():125-31. PubMed ID: 25227564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.